Glassman Wealth Services Bei Gene, Ltd. Transaction History

Glassman Wealth Services

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$158.67 - $201.58 $634 - $806	-4 Reduced 11.76%	30 $5,000
Q3 2023 Nov 13, 2023	BUY	$179.87 - $225.13 $2,158 - $2,701	12 Added 54.55%	34 $6,000
Q1 2023 May 04, 2023	BUY	$215.53 - $274.5 $646 - $823	3 Added 15.79%	22 $4,000
Q4 2022 Feb 06, 2023	BUY	$125.51 - $229.3 $2,133 - $3,898	17 Added 850.0%	19 $4,000
Q2 2022 Aug 04, 2022	BUY	$121.11 - $216.05 $242 - $432	2 New	2 $0
Q1 2022 Apr 14, 2022	SELL	$146.52 - $269.56 $293 - $539	-2 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $248 - $389	1 Added 100.0%	2 $1,000
Q3 2021 Nov 10, 2021	BUY	$249.6 - $403.14 $249 - $403	1 New	1 $0

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

Stay updated on Glassman Wealth Services with notifications on news.